[Treatment with 32P of carcinoma of the prostate (author's transl)].
Twenty-eight patients affected with disseminated prostate cancer, which proved hormone resistant (after castration and oestrogen administration), have undergone combined treatment with Testosterone (for 13 days) and 32P (for the last 7 days of the Testosterone treatment). During the initial fase of the treatment (Testosterone only), 14 patients experienced pain exacerbation and/or fever and one experienced immediate improvement. The exacerbation quickly disappeared following 32P administration, and 26 of the patients had distinct improvement at some time during or after treatment, with a mean remission duration of 3 months and mean survival rate of 7 months. No lytic or soft part deposit showed improvement; improvement was noticeable only in the mixed type or osteo-sclerotic metastases. This observation suggests that the androgen stimulates uptake of the isotope not inside the tumor cells but in the bone matrix around the tumoral deposit. The patient who showed very early improvement had a subsequent relapse on oestrogens, but later responded to the androgen alone.
D006801:Humans; D008297:Male; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*
D010761:Phosphorus Radioisotopes; D013739:Testosterone
Trattamento con radiofosforo del carcinoma della prostata